Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
Editor’s note: We at The Rheumatologist are saddened to hear of the passing of Richard Brasington Jr., MD, FACP, MACR. Dr. Brasington leaves a legacy of excellence as an outstanding clinician, educator, scholar and more. One of the many ways that he contributed to our community was as the associate editor of The Rheumatologist between…
Editor’s note: We at The Rheumatologist are saddened to hear of the passing of Richard Brasington Jr., MD, FACP, MACR. Dr. Brasington leaves a legacy of excellence as an outstanding clinician, educator, scholar and more. One of the many ways that he contributed to our community was as the associate editor of The Rheumatologist between…
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
With an influx of new faces in the 118th Congress, Government Affairs Committee Chair Christina Downey, MD, notes that now is a great time to establish a relationship with your member of Congress and help them understand the day-to-day of what it takes to take care of patients.
In a study, El Bannoudi et al. found that platelets contribute to the pathogenesis of SLE by secreting the proinflammatory platelet-associated lectin, galactoside-binding, soluble 3 binding protein (LGALS3BP), which also represents a novel biomarker of SLE clinical activity.
Value-based care in rheumatology continues to evolve, and rheumatologists can stay active with advocacy efforts behind value-based care and other government relations initiatives.
Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…
As COVID-19 case counts fade from the headlines and people return to their pre-pandemic routines, rheumatologists and rheumatology professionals may be wondering what “the end” of COVID-19 is going to look like for them. Much of that answer lies in the status of the federal emergencies that have been declared in response to COVID-19. These…